Ceapro Inc (TSE:CZO) has released an update.
Ceapro Inc. has received final court approval for its all-stock merger with Aeterna Zentaris, with completion expected in the second quarter of 2024. The merger aims to combine Ceapro’s expertise in natural product extraction and Aeterna’s biopharmaceutical development, targeting areas with significant unmet medical needs. Investors can find further details on the transaction in the management information circulars available on the SEDAR+ and EDGAR websites.
For further insights into TSE:CZO stock, check out TipRanks’ Stock Analysis page.
